

The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



長春達興藥業股份有限公司

CHANGCHUN DA XING PHARMACEUTICAL COMPANY LIMITED*

(a joint stock limited company incorporated in the People's Republic of China)

(Stock code: 8067)

**APPOINTMENT OF
INDEPENDENT NON-EXECUTIVE DIRECTOR
AND
AUDIT COMMITTEE MEMBER**

The Board is pleased to announce that Mr. Zhang Zhong Sheng was appointed as an independent non-executive director and audit committee member of the Company with effect from 25 May 2004.

Pursuant to the resolution passed in the annual general meeting of the Company (the “AGM”) on 14 May 2004, the board of directors of the Company (the “Board”) is pleased to announce that **Mr. Zhang Zhong Sheng** (張宗生) (“Mr. Zhang”) has been appointed as an independent non-executive director and audit committee member of the Company with effect from 25 May 2004 until the date of annual general meeting to be held in 2005. According to his service agreement with the Company, Mr. Zhang is not entitled to any salary or fee during his term of service as an independent non-executive director of the Company.

Mr. Zhang, aged 33, is a Chinese Certified Public Accountant. Mr. Zhang graduated from Dongbei University of Finance and Economics (東北財經大學) in 1994 with a bachelor degree in Economics. Mr. Zhang is currently the president of Huaan Certified Public Accountants (華安會計師事務所) with approximately ten years experience in financial auditing including auditing of listed companies. Mr. Zhang has also been appointed as an independent director of another PRC incorporated joint stock limited company listed on the Shanghai Stock Exchange of PRC since November, 2000.

* For identification only

Mr. Zhang has no interests in shares of the Company within the meaning of Part XV of the SFO. Mr. Zhang has no relationship with any directors, senior management, management shareholders, substantial shareholders or controlling shareholders of the Company (within the meaning of the GEM Listing Rules). Save as disclosed herein, the Board is not aware of any other matters which need to be brought to the attention of the shareholders of the Company.

The Board would like to welcome Mr. Zhang for joining the Company.

By Order of the Board
YAU Wing Yiu
Company Secretary

Hong Kong, 25 May 2004

As at the date of this announcement the Board comprises five executive directors, being Feng Zhen Wen, Yu Cheng Kun, Li Xiu Jie, Guo Bin and Lu Yin Hua; a non-executive director, Lu De Yi; and three independent non-executive directors, being Yang Shi Jie, Sun Xiao Bo and Zhang Zhong Sheng.

This announcement, for which the directors of Changchun Da Xing Pharmaceutical Company Limited collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to Changchun Da Xing Pharmaceutical Company Limited. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (i) the information contained in this announcement is accurate and complete in all material respects and not misleading; (ii) there are no other matters the omission of which would make any statement in this announcement misleading; and (iii) all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.

This announcement will remain on the “Latest Company Announcements” page of the GEM website at <http://www.hkgem.com> for at least 7 days from the date of its posting.